Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAE226 |
Synonyms | |
Therapy Description |
TAE226 is a dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor, (IGFIR) resulting in decreased signaling pathway activation, decreased tumor cell growth and invasion, and increased cell-cycle arrest (PMID: 17431114, PMID: 31692287). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAE226 | FAK inhibitor 15 IGF-1R Inhibitor 17 | TAE226 is a dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor, (IGFIR) resulting in decreased signaling pathway activation, decreased tumor cell growth and invasion, and increased cell-cycle arrest (PMID: 17431114, PMID: 31692287). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK | lung non-small cell carcinoma | sensitive | TAE226 | Preclinical | Actionable | In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EML4-ALK fusion in culture (PMID: 26090892). | 26090892 |
BRAF G469A | lung non-small cell carcinoma | sensitive | TAE226 | Preclinical | Actionable | In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892). | 26090892 |
BRAF G466V | lung non-small cell carcinoma | sensitive | TAE226 | Preclinical | Actionable | In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892). | 26090892 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|